IBRX is trading 3.9% down at $7.74 today as the stock undergoes profit-taking and consolidation following a sharp rally triggered by positive regulatory news.
- The FDA accepted the company's supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG in BCG-unresponsive bladder cancer on May 20, 2026.
- Today's decline appears to be a technical retracement after the recent news-driven spike, with no fresh company-specific headlines reported.
- Broader market indices are also trading slightly in the red, contributing to the downward pressure on the share price.